A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
The main inclusion criteria include but are not limited to the following:
Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
Cohort B1: VHL Disease-associated tumors:
Has a life expectancy of at least 3 months
The main exclusion criteria include but are not limited to the following:
Trialsites@msd.com1-888-577-8839
Los Angeles, California 90048, United States
310-967-2781
Chicago, Illinois 60611, United States
Warrenville, Illinois 60555, United States
Baltimore, Maryland 21287, United States
St Louis, Missouri 63110, United States
New York, New York 10029, United States
Philadelphia, Pennsylvania 19104, United States
Nashville, Tennessee 37232, United States
Houston, Texas 77030, United States
Randwick, New South Wales 2031, Australia
Calgary, Alberta T2N 5G2, Canada
Santiago, Region M. de Santiago 7560908, Chile
Beijing, Beijing Municipality 100034, China
Guangzhou, Guangdong 510060, China
Shanghai, Shanghai Municipality 200001, China
Copenhagen, Capital Region 2100, Denmark
Strasbourg, Alsace 67098, France
Marseille, Bouches-du-Rhone 13009, France
Le Kremlin-Bicêtre, Paris 94270, France
Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
München, Bavaria 80336, Germany
Würzburg, Bavaria 97080, Germany
Düsseldorf, North Rhine-Westphalia 40225, Germany
Berlin, 10117, Germany
Budapest, 1083, Hungary
Ramat Gan, 5262100, Israel
Naples, Campania 80100, Italy
Milan, Lombardy 20133, Italy
Siena, Tuscany 53100, Italy
Bologna, 40138, Italy
Milan, 20141, Italy
Yokohama, Kanagawa 236-0004, Japan
Chuo-ku, Tokyo 104-0045, Japan
Tokyo, 123-8558, Japan
Lisbon, Lisbon District 1649-035, Portugal
Porto, 4200-072, Portugal
Ufa, Baskortostan, Respublika 450054, Russia
Saint Petersburg, Leningradskaya Oblast' 190020, Russia
Saint Petersburg, Leningradskaya Oblast' 198255, Russia
Moscow, Moscow 115522, Russia
Moscow, Moscow 117036, Russia
Singapore, Central Singapore 168583, Singapore
Jongno-gu, Seoul 03080, South Korea
82-2-2072-3618
Songpa-gu, Seoul 05505, South Korea
82-2-3010-3266
Madrid, Madrid, Comunidad de 28041, Spain
Oviedo, Principality of Asturias 33011, Spain
Stockholm, Stockholm County 171 76, Sweden
Uppsala, Uppsala County 751 85, Sweden
Gothenburg, Västra Götaland County 413 45, Sweden
Yüreğir, Adana 01250, Turkey (Türkiye)
Istanbul, 34668, Turkey (Türkiye)
Glasgow, Glasgow City G12 0YN, United Kingdom
312-695-1310
312-695-1310
319-356-2148
410-502-5140
240-858-3851
617-724-4000
734-647-8902
615-329-7274
800-811-8480
713-792-2841
+61402035933
+61 3 9342 7143
403-521-3165
416-946-4501 x6508
56224205098
+56225189885
+45 35453545
35457562
+45 66 11 33 33
+(0)3 88 12 75 93
+33472119692
0145217453
+33158411439
+49761270-32613
49-0931-20 13 90 21
+49 211 81 08030
+4930450614303
+3614591500
+97235303030
+97236972062
0223902182
+39057758636
+ 39 051 2142708
+390303995410
+390257489258
+390458128131
31887556308
+4722934000
+351 21 780 5000
(351) 225 084 000
+65 64368000
34913908926
34646662756
34934894350
+4646171000
+46186110000
+46313421000
+904449901
00902323903911
00903123052910
0090312 552 60 00
+441223245151
+44 141 301 7055
0208 383 3089